A systematic review of methods used to conduct decentralised clinical trials.

Authors:
Rogers A; De Paoli G; Subbarayan S; Copland R; Harwood K and 5 more

Journal:
Br J Clin Pharmacol

Publication Year: 2022

DOI:
10.1111/bcp.15205

PMCID:
PMC9306873

PMID:
34961991

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Br J Clin Pharmacol

Abbreviation: Br J Clin Pharmacol

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Pharmacology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Phase 1 safety, tolerability, pharmacokinetics and pharmacodynamic results of KCL-286, a novel reti…
Goncalves MB; Mant T; Täubel J and 8 more (2023) - Transparency Score: 4/6
A comprehensive pharmacogenomic study indicates roles for SLCO1B1, ABCG2 and SLCO2B1 in rosuvastati…
Lehtisalo M; Taskinen S; Tarkiainen EK and 8 more (2022) - Transparency Score: 3/6
A crossover study evaluating the sex-dependent and sensitizing effects of sleep deprivation using a…
Hijma H; Koopmans I; Klaassen E and 3 more (2022) - Transparency Score: 4/6
Acute response to cholinergic challenge predicts long-term response to galantamine treatment in pat…
Baakman AC; Gavan C; van Doeselaar L and 12 more (2022) - Transparency Score: 4/6
An e-Delphi study to obtain expert consensus on the level of risk associated with preventable e-pre…
Heed J; Klein S; Slee A and 3 more (2022) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
4/6
66.7% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"COMPETING INTERESTS The authors declare current or recent research income to their institution from Novartis, Pfizer, GSK, Menarini, IMI, EMA, NIHR HTA, BHF, Amgen, RTI, CSO Scotland, Tenovus Scotland, George Clinical, Sanofi and HDR UK, and consultancy income to their institution from AstraZeneca. ISM declares personal consultancy income from AstraZeneca. TMM declares consulting or speaking fees in the last 5 years from Novartis, Takeda, Servier, Shire, Menarini and AstraZeneca."

Evidence found in paper:

"Funding information Innovative Medicines Initiative, Grant/Award Numbers: 831458, 831 458"

Evidence found in paper:

"A systematic review protocol was developed a priori and registered on the International Prospective Register of Systematic Reviews (PROSPERO, CRD42020166710)."

Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025